Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caffeine + propranolol is a combination of two active pharmaceutical ingredients, caffeine and propranolol. Caffeine is a central nervous system stimulant of the methylxanthine class, commonly used to promote wakefulness and as an adjuvant in pain relief medications. Propranolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) used primarily for the treatment of hypertension, angina pectoris, arrhythmias, migraine prophylaxis, essential tremor, and anxiety. The combination does not have a widely recognized or marketed fixed-dose formulation but may be co-administered in clinical practice for specific indications such as migraine management or to counteract certain side effects (e.g., performance anxiety with fatigue). Caffeine acts by antagonizing adenosine receptors leading to increased alertness and mild vasoconstriction; propranolol blocks beta-1 and beta-2 adrenergic receptors resulting in decreased heart rate, contractility, blood pressure reduction, and inhibition of sympathetic nervous system activity[3][4][7][8]. There are no major direct pharmacological interactions between these two drugs; however, caffeine can reduce the antihypertensive effect of propranolol due to its pressor action[2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + propranolol.